• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20338 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Hybrid closed-loop insulin delivery systems for people with Type 1 diabetes
2021     Health Technology Wales (HTW) Transcranial magnetic stimulation for the treatment of depression
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Mistletoe therapy with breast cancer]
2021     NIHR Health Technology Assessment programme BioImpedance Spectroscopy To maintain Renal Output: the BISTRO trial
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (seizures in tuberous sclerosis complex) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Coping strategies in complex medical situations - the example of coronary heart disease]
2021     NIHR Health Services and Delivery Research programme Models of generalist and specialist care in smaller acute hospitals: an exploratory study
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: noninvasive fetal RhD genotyping using maternal plasma]
2021     Scottish Health Technologies Group (SHTG) Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The potential influence of socio-demographical factors on access to and results of rehabilitation]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tucatinib (breast cancer) - Addendum to Commission A21-26]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice venetoclax (Venclyxto®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Speech therapy for aphasia]
2021     Swiss Federal Office of Public Health (FOPH) Statins in the primary prevention of cardiovascular events and mortality in Switzerland
2021     NIHR Health Technology Assessment programme Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: microbiological stool testing in adults and children with diarrhea: relevance and measures to promote judicious use]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35]
2021     Swiss Federal Office of Public Health (FOPH) Vertebroplasty or kyphoplasty in painful osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: pertussis - diagnostic modalities and trajectory]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma, adjuvant) - Addendum to Commission A21-39]
2021     Swiss Federal Office of Public Health (FOPH) Chondroitin sulfate in osteoarthritis
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Addendum to commission H20-01]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment for postpartum psychiatric disorders - an evidence map]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice drospirenon-estetrol (Drovelis®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Perioperative antibiotics for prevention of infections in arterial reconstructions with vascular prostheses]
2021     NIHR Health Technology Assessment programme DRAFFT 2: Distal Radius Acute Fracture Fixation Trial 2
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on the reassessment of tafamidis (Vyndaqel®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2021     Center for Evidence-based Practice (CEP) Venous irritation resulting from IV fosaprepitant
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: artificial intelligence-assisted diabetic retinopathy tele-screening]
2021     Center for Evidence-based Practice (CEP) Oral hygiene interventions to prevent ventilator-associated pneumonia (VAP)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on subcutaneous buprenorphine (Buvidal®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     Malaysian Health Technology Assessment (MaHTAS) Driving simulator in healthcare
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     NIHR Health Technology Assessment programme Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Technology Assessment programme The Prognosis in Palliative care Study II (PiPS2)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021     The Federal Joint Committee (G-BA) Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Berotralstat (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [National expert standards in nursing care]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice for cladribine (Mavenclad®) – extension of further conditions
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of calcifediol (Hidroferol®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A20-61]
2021     NIHR Health Technology Assessment programme Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation
2021     Malaysian Health Technology Assessment (MaHTAS) Delirium unit in geriatric ward
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice niraparib (Zejula®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon catheter for the transurethral treatment of urethral strictures - Second addendum to commission H20-02]
2021     NIHR Health Technology Assessment programme Fall prevention interventions in primary care to reduce fractures and falls in people aged 70 years and over: the PreFIT three-arm cluster RCT
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice SGLT-2 inhibitors
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery (SRS) for the treatment of vestibular schwannoma requiring intervention]
2021     Malaysian Health Technology Assessment (MaHTAS) Digital assisted oral & cranio-maxillofacial surgery
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Malaysian Health Technology Assessment (MaHTAS) Platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - health economic evaluation
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]